Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence.

Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM.

Prostate. 2013 Dec;73(16):1786-95. doi: 10.1002/pros.22717. Epub 2013 Aug 29.

2.

Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk.

Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA, Yeager M, Weinstein SJ, Snyder K, Virtamo J, Albanes D.

Cancer Res. 2009 Feb 15;69(4):1429-38. doi: 10.1158/0008-5472.CAN-08-2343. Epub 2009 Feb 3.

3.

Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.

Nordström T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, Simko J, Carroll PR, Chan JM, Paris PL.

Prostate. 2016 Mar;76(4):339-48. doi: 10.1002/pros.23125. Epub 2015 Nov 20.

4.

Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence.

Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, Carroll PR, Chan JM.

Prostate. 2015 Jan;75(1):60-9. doi: 10.1002/pros.22892. Epub 2014 Oct 4.

5.

Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study.

Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB.

Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6. Epub 2007 Jul 23.

6.

Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival.

Van Blarigan EL, Ma J, Kenfield SA, Stampfer MJ, Sesso HD, Giovannucci EL, Witte JS, Erdman JW Jr, Chan JM, Penney KL.

Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1037-46. doi: 10.1158/1055-9965.EPI-13-0670. Epub 2014 Apr 7.

7.

Genetic variation in myeloperoxidase modifies the association of serum α-tocopherol with aggressive prostate cancer among current smokers.

Cheng TY, Barnett MJ, Kristal AR, Ambrosone CB, King IB, Thornquist MD, Goodman GE, Neuhouser ML.

J Nutr. 2011 Sep;141(9):1731-7. doi: 10.3945/jn.111.141713. Epub 2011 Jul 27.

8.

Serum α-tocopherol and γ-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study.

Weinstein SJ, Peters U, Ahn J, Friesen MD, Riboli E, Hayes RB, Albanes D.

PLoS One. 2012;7(7):e40204. doi: 10.1371/journal.pone.0040204. Epub 2012 Jul 5.

9.

Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.

Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM.

BJU Int. 2011 Jan;107(1):126-34. doi: 10.1111/j.1464-410X.2010.09344.x.

10.

Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study.

Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, Virtamo J, Albanes D.

J Natl Cancer Inst. 2005 Mar 2;97(5):396-9.

PMID:
15741576
11.

Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer.

Major JM, Yu K, Weinstein SJ, Berndt SI, Hyland PL, Yeager M, Chanock S, Albanes D.

J Nutr. 2014 May;144(5):729-33. doi: 10.3945/jn.113.189928. Epub 2014 Mar 12.

12.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29.

13.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR.

Eur Urol. 2014 Sep;66(3):550-60. doi: 10.1016/j.eururo.2014.05.004. Epub 2014 May 16.

14.

Effects of polymorphisms in vitamin E-, vitamin C-, and glutathione peroxidase-related genes on serum biomarkers and associations with glaucoma.

Zanon-Moreno V, Asensio-Marquez EM, Ciancotti-Oliver L, Garcia-Medina JJ, Sanz P, Ortega-Azorin C, Pinazo-Duran MD, Ordovás JM, Corella D.

Mol Vis. 2013;19:231-42. Epub 2013 Feb 3.

15.

Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland).

Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D.

Cancer Causes Control. 2003 Aug;14(6):513-8.

PMID:
12948282
16.

Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, Black A, Boeing H, Bueno-de-Mesquita HB, Chan JM, Chen C, Cook MB, Donovan JL, Galan P, Gilbert R, Giles GG, Giovannucci E, Goodman GE, Goodman PJ, Gunter MJ, Hamdy FC, Heliövaara M, Helzlsouer KJ, Henderson BE, Hercberg S, Hoffman-Bolton J, Hoover RN, Johansson M, Khaw KT, King IB, Knekt P, Kolonel LN, Le Marchand L, Männistö S, Martin RM, Meyer HE, Mondul AM, Moy KA, Neal DE, Neuhouser ML, Palli D, Platz EA, Pouchieu C, Rissanen H, Schenk JM, Severi G, Stampfer MJ, Tjønneland A, Touvier M, Trichopoulou A, Weinstein SJ, Ziegler RG, Zhou CK, Allen NE; Endogenous Hormones Nutritional Biomarkers Prostate Cancer Collaborative Group.

Am J Clin Nutr. 2015 Nov;102(5):1142-57. doi: 10.3945/ajcn.115.114306. Epub 2015 Oct 7.

17.

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.

BJU Int. 2013 May;111(6):921-7. doi: 10.1111/j.1464-410X.2012.11665.x. Epub 2013 Jan 25.

18.

Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.

Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT.

Int J Cancer. 2006 Oct 15;119(8):1902-7.

19.

Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.

Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY.

Int J Cancer. 2014 Dec 1;135(11):2661-7. doi: 10.1002/ijc.28904. Epub 2014 Apr 22.

20.

Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.

Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ.

Int J Urol. 2015 Apr;22(4):362-6. doi: 10.1111/iju.12704. Epub 2015 Feb 24.

Supplemental Content

Support Center